Sixteen new procedure and two diagnostics codes added to private reimbursement schedule in England

11

Jun 2019

The Clinical Coding and Schedule Development (CCSD) group develop and maintains procedural and diagnostics nomenclature for private payers in England. New procedure codes concern cytoreductive surgery for colorectal peritoneal carcinomatosis, cytoreductive surgery for ovarian malignancies, therapeutic sialendoscopy, intra corporeal salivary gland lithotripsy, bronchial thermoplasty and others and diagnostic codes for tests for common and rare mutations. The codes are introduced with a recommended adoption date being the 1st of August 2019. The documents also contain a list of textual changes in codes and an updated list of unacceptable combinations of codes.

The CCSD Group has approved the following procedure codes for publication to the CCSD Schedule in April 2019 with a recommended adoption date being the 1st of August 2019:

  • Therapeutic sialendoscopy (including stone retrieval +/- dilation) (F4831)
  • Intracorporeal salivary gland lithotripsy (F4832)
  • Combined open and endoscopic removal of submandibular gland stone (F5121)
  • Combined open and endoscopic removal of parotid gland stone (F5611)
  • Minimally invasive endoscopic repair of atrial septal defects (ASD) via mini-thoracotomy (K0960)
  • Transabdominal cerclage for cervical incompetence in gravid uterus (R1230)
  • Laparoscopic cerclage for cervical incompetence in gravid uterus (R1240)
  • Bronchial thermoplasty (including bronchoscopy) for severe asthma (E6710)
  • Harvesting and injection of bone marrow aspirate concentrate (BMAC) (W7180)
  • Cytoreductive surgery (Sugarbaker technique) for Pseudomyxoma Peritonei with intraperitoneal chemotherapy (J9901)
  • Cytoreductive surgery for Colorectal Peritoneal Carcinomatosis (2-3 distinct procedures) with intraperitoneal chemotherapy (J9902)
  • Cytoreductive surgery for Colorectal Peritoneal Carcinomatosis (4-6 distinct procedures) with intraperitoneal chemotherapy (J9903)
  • Cytoreductive surgery for Colorectal Peritoneal Carcinomatosis (7-8 distinct procedures) with intraperitoneal chemotherapy (J9904)
  • Repeat Cytoreductive surgery for Pseudomyxoma Peritonei or Colorectal Peritoneal Carcinomatosis with intraperitoneal chemotherapy (J9905)
  • Heated intraperitoneal chemotherapy for Colorectal Peritoneal Carcinomatosis (J9906)
  • Cytoreductive surgery for Ovarian Malignancies excluding intraperitoneal chemotherapy (J9907)

See full details here.

The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in April 2019 with a recommended adoption date being the 1st of August 2019:

  • 5FU Common mutations (DPD) (0633G)
  • 5FU Rare mutations (DPD) (0634G)

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

21

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more